Global Medical Genetics (Dec 2024)

Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors

  • Chunwei Xu,
  • Bin Lian,
  • Juanjuan Ou,
  • Qian Wang,
  • Wenxian Wang,
  • Ke Wang,
  • Dong Wang,
  • Zhengbo Song,
  • Aijun Liu,
  • Jinpu Yu,
  • Wenzhao Zhong,
  • Zhijie Wang,
  • Yongchang Zhang,
  • Jingjing Liu,
  • Shirong Zhang,
  • Xiuyu Cai,
  • Anwen Liu,
  • Wen Li,
  • Lili Mao,
  • Ping Zhan,
  • Hongbing Liu,
  • Tangfeng Lv,
  • Liyun Miao,
  • Lingfeng Min,
  • Yu Chen,
  • Jingping Yuan,
  • Feng Wang,
  • Zhansheng Jiang,
  • Gen Lin,
  • Long Huang,
  • Xingxiang Pu,
  • Rongbo Lin,
  • Weifeng Liu,
  • Chuangzhou Rao,
  • Dongqing Lv,
  • Zongyang Yu,
  • Xiaoyan Li,
  • Chuanhao Tang,
  • Chengzhi Zhou,
  • Junping Zhang,
  • Junli Xue,
  • Hui Guo,
  • Qian Chu,
  • Rui Meng,
  • Jingxun Wu,
  • Rui Zhang,
  • Jin Zhou,
  • Zhengfei Zhu,
  • Yongheng Li,
  • Hong Qiu,
  • Fan Xia,
  • Yuanyuan Lu,
  • Xiaofeng Chen,
  • Rui Ge,
  • Enyong Dai,
  • Yu Han,
  • Weiwei Pan,
  • Fei Pang,
  • Jintao Huang,
  • Kai Wang,
  • Fan Wu,
  • Bingwei Xu,
  • Liping Wang,
  • Youcai Zhu,
  • Li Lin,
  • Yanru Xie,
  • Xinqing Lin,
  • Jing Cai,
  • Ling Xu,
  • Jisheng Li,
  • Xiaodong Jiao,
  • Kainan Li,
  • Jia Wei,
  • Huijing Feng,
  • Lin Wang,
  • Yingying Du,
  • Wang Yao,
  • Xuefei Shi,
  • Xiaomin Niu,
  • Dongmei Yuan,
  • Yanwen Yao,
  • Jianhui Huang,
  • Yue Feng,
  • Yinbin Zhang,
  • Pingli Sun,
  • Hong Wang,
  • Mingxiang Ye,
  • Zhaofeng Wang,
  • Yue Hao,
  • Zhen Wang,
  • Bin Wan,
  • Donglai Lv,
  • Zhanqiang Zhai,
  • Shengjie Yang,
  • Jing Kang,
  • Jiatao Zhang,
  • Chao Zhang,
  • Lin Shi,
  • Yina Wang,
  • Bihui Li,
  • Zhang Zhang,
  • Zhongwu Li,
  • Zhefeng Liu,
  • Nong Yang,
  • Lin Wu,
  • Huijuan Wang,
  • Gu Jin,
  • Guansong Wang,
  • Jiandong Wang,
  • Meiyu Fang,
  • Yong Fang,
  • Yuan Li,
  • Xiaojia Wang,
  • Jing Chen,
  • Yiping Zhang,
  • Xixu Zhu,
  • Yi Shen,
  • Shenglin Ma,
  • Biyun Wang,
  • Lu Si,
  • Yuanzhi Lu,
  • Ziming Li,
  • Wenfeng Fang,
  • Yong Song

DOI
https://doi.org/10.1055/s-0044-1790230
Journal volume & issue
Vol. 11, no. 04
pp. 330 – 343

Abstract

Read online

The fibroblast growth factor receptor (FGFR) is a crucial receptor tyrosine kinase involved in essential biological processes, including growth, development, and tissue repair. However, FGFR gene mutations, including amplification, fusion, and mutation, can disrupt epigenetics, transcriptional regulation, and tumor microenvironment interactions, leading to cancer development. Targeting these kinase mutations with small molecule drugs or antibodies has shown clinical benefits. For example, erdafitinib is approved for treating locally advanced or metastatic urothelial cancer patients with FGFR2/FGFR3 mutations, and pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement. Effective screening of FGFR variant patients is crucial for the clinical application of FGFR inhibitors. Various detection methods, such as polymerase chain reaction, next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry, are available, and their selection should be based on diagnostic and treatment decision-making needs. Our developed expert consensus aims to standardize the diagnosis and treatment process for FGFR gene mutations and facilitate the practical application of FGFR inhibitors in clinical practice.

Keywords